D. Boral Capital Reaffirms “Buy” Rating for Context Therapeutics (NASDAQ:CNTX)

Context Therapeutics (NASDAQ:CNTX)‘s stock had its “buy” rating reissued by D. Boral Capital in a report released on Thursday,Benzinga reports. They presently have a $9.00 target price on the stock.

A number of other brokerages also recently issued reports on CNTX. HC Wainwright boosted their price target on shares of Context Therapeutics from $4.00 to $5.00 and gave the stock a “buy” rating in a research report on Thursday. Guggenheim assumed coverage on shares of Context Therapeutics in a report on Thursday, September 18th. They issued a “buy” rating and a $5.00 target price on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Context Therapeutics in a research report on Wednesday, October 8th. Finally, Cantor Fitzgerald initiated coverage on Context Therapeutics in a research report on Thursday, October 2nd. They issued an “overweight” rating for the company. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $5.40.

Context Therapeutics Trading Up 4.7%

NASDAQ CNTX opened at $1.12 on Thursday. The firm has a market capitalization of $100.47 million, a PE ratio of -4.67 and a beta of 1.94. The business’s 50-day moving average price is $1.07 and its two-hundred day moving average price is $0.85. Context Therapeutics has a 12 month low of $0.49 and a 12 month high of $2.10.

Context Therapeutics (NASDAQ:CNTX) last issued its quarterly earnings data on Wednesday, November 5th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.01). As a group, analysts forecast that Context Therapeutics will post -0.51 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Context Therapeutics

An institutional investor recently raised its position in Context Therapeutics stock. Clear Harbor Asset Management LLC boosted its position in Context Therapeutics Inc. (NASDAQ:CNTX) by 60.5% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 92,804 shares of the company’s stock after buying an additional 35,000 shares during the period. Clear Harbor Asset Management LLC owned approximately 0.10% of Context Therapeutics worth $90,000 at the end of the most recent quarter. 14.03% of the stock is currently owned by hedge funds and other institutional investors.

Context Therapeutics Company Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.